Technology Transition Sample Clauses

Technology Transition. Describe how the technology will be transitioned during and after the termination of the CRADA. The recommended result could be one or more of several examples:
Sample 1Sample 2
AutoNDA by SimpleDocs
Technology Transition. If, on or before the date of the scheduled Closing, Seller and Purchaser shall not have completed all of the information and technology transfer and migration tasks contemplated by Sections 5.6(b) and 5.6(d), then the Closing shall be delayed until the first Business Day following the date on which the last of the transfer and migration activities described in Sections 5.6(b) and 5.6(d) shall have been completed; provided, however, that the Closing Date shall not be delayed pursuant to this Section 2.1(d) beyond June 28, 2013.
Sample 1
Technology Transition. For a period not to exceed sixty (60) days following the Closing Date, the Seller will provide, at no additional charge, (i) reasonable technical assistance to Buyer with regards to the transfer of all IP related Purchased Assets together with (ii) reasonable training on the operation of and how to support the operation of all of the URL portals listed on Exhibit “A”.
Sample 1
Technology Transition. Seller shall fulfill its obligation with regard to the transition of technology as set forth in Section 5.4.
Sample 1
Technology Transition. The Institute’s business plan and strategy to effect technology transition are critical to its long-term success, financial self-sufficiency, and economic impact. The technology transition strategy will affect the Institute management plan, technical focus areas, intellectual property and data management, and personnel. The Institute’s technology transition activities shall exercise fully its "industrial commons" and needs to be integral in the selection process for the Institute’s technical projects. There are several metals manufacturing technologies that the DoD has interest in scaling up from MRL 4 to MRL 7, and into production (MRL 8-9). These include, but are not limited to, the manufacturing of low-cost and high performing metal components and assemblies for lightweight ground, aerospace, and maritime systems; applications utilizing advanced alloys (e.g., titanium-, aluminum- and magnesium-based alloys and processing) and novel materials architectures (e.g., metallic foams, cellular structures, etc.) that reduce system weight; and materials for lightweight high-efficiency engines. The DoD also envisions that other government agencies will have similar manufacturing problems of interest for the LM3I Institute. These manufacturing challenges present practical objectives that can lead to new products for market expansion. They also allow engineers and researchers to address the core technology challenges associated with lightweight design in an integrated manner, using processes including ICME and its associated tools. As an initial example, four core metals manufacturing technology areas of interest for the LM3I Institute are: (1) applications of new/novel metals and alloys; (2) primary metal manufacturing processes; (3) secondary manufacturing processes; and (4) development of products exploiting lightweight and modern metals. It is recognized that a critical component of transition includes education and workforce development. Further, this list is not all-inclusive, and another categorization of the core technologies may offer superior utility.
Sample 1

Related to Technology Transition

  • Technology Transfer Subject to the terms of the Development Supply Agreement, as soon as reasonably practicable, but in no event later than the fifth (5th) anniversary of the Effective Date, Alnylam shall initiate a technology transfer to MedCo, or to its Third Party manufacturer(s) of Licensed Product, selected by MedCo and reasonably acceptable to Alnylam, of Alnylam Know-How that is reasonably necessary or useful for the Manufacture of the Licensed Product, and shall make available its personnel on a reasonable basis to consult with MedCo or such Third Party manufacturer(s) with respect thereto, all at MedCo’s expense, including the Costs reasonably incurred by Alnylam in connection with such technology transfer activities. MedCo shall reimburse Alnylam such Costs incurred with respect to such Manufacturing technology transfer within [***] days after receipt of an invoice therefor. Alnylam and its Affiliates shall keep complete and accurate records in sufficient detail to enable the payments payable hereunder to be determined. Alnylam shall not be required to perform technology transfer to more than one Third Party manufacturer for each stage of the Licensed Product supply chain (i.e., Bulk Drug Substance, Bulk Drug Product and Finished Product). Promptly after MedCo’s written request, Alnylam shall use Commercially Reasonable Efforts to assign to MedCo any manufacturing agreement between Alnylam and a Third Party that is solely related to the manufacture of Licensed Products. Such assignment shall be subject to the terms and conditions of such agreement, including any required consents of such Third Party and MedCo’s written agreement to assume all the obligations of Alnylam under such agreement to be undertaken after such assignment, but Alnylam shall remain solely responsible for its obligations under such agreement arising prior to such assignment. Except as provided in the immediately preceding sentence, MedCo shall be solely responsible for contracting with such Third Party manufacturer (and any other Third Party manufacture to whom Alnylam has initiated technology transfer as set forth in this Section 5.3) for the supply of such Licensed Product and Alnylam shall have no obligations under such agreement between MedCo and such Third Party manufacturer. Alnylam shall use Commercially Reasonable Efforts to obtain any such consent in a form reasonably acceptable to MedCo.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Initial Development Plan Not later than the Effective Date, Licensee shall have provided Merck with an initial Development plan for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Attachment 3.02(a) (as may be amended in accordance with this Agreement, the “Development Plan”). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Transition Seller will not take any action that is designed or intended to have the effect of discouraging any lessor, licensor, customer, supplier, or other business associate of the Company from maintaining the same business relationships with the Company after the Closing as it maintained with the Company prior to the Closing. The Seller will refer all customer inquiries relating to the business of the Company to the Purchaser from and after the Closing.

  • Technology License 4.1 Unless any event described in Article 2.2 or 2.3 of this Agreement occurs, all of the technology required to be licensed for any of Party B’s business shall be provided by Party A on an exclusive basis. Party A will try its best to license Party B to use the technology owned by Party A, or re-license Party B to use the technology as approved by the owner.

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Information Systems Acquisition Development and Maintenance Security of System Files. To protect City Information Processing Systems and system files containing information, Service Provider will ensure that access to source code is restricted to authorized users whose specific job function necessitates such access.

  • Transition Planning The AGENCY will be responsible for the development of the student’s Transition Plan, which begins upon entry and is completed prior to the student’s exit.

Time is Money Join Law Insider Premium to draft better contracts faster.